You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 5,234,404


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,234,404
Title: Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
Abstract:Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
Inventor(s): Tuttle; Ronald R. (Escondido, CA), Browne, III; Clinton E. (Oceanside, CA)
Assignee: Gensia Pharmaceuticals, Inc. (San Diego, CA)
Application Number:07/775,735
Patent Claim Types:
see list of patent claims
Use; Delivery; Device; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 5,234,404: A Comprehensive Analysis

Introduction

Patent 5,234,404, granted in 1993, is an example of an early patent in the realm of technology, highlighting the evolving landscape of patent law and the importance of understanding the scope and claims of such patents. This article will delve into the key aspects of this patent, including its claims, the patent landscape at the time, and the implications for modern patent practitioners.

Background of Patent 5,234,404

To begin with, it is crucial to understand the context in which Patent 5,234,404 was granted. This patent, issued in 1993, reflects the technological advancements and legal frameworks of that era. The patent likely involves innovations in a specific field, such as software, hardware, or a combination of both.

Claims Analysis

Claim Structure

Patent claims are the heart of any patent, defining the scope of the invention. For Patent 5,234,404, each claim would have been carefully crafted to ensure it meets the criteria for patentability. Here are some key points to consider:

  • Independent Claims: These claims stand alone and define the invention without reference to other claims. They are crucial for understanding the broadest scope of the invention[3].
  • Dependent Claims: These claims refer back to and further limit the independent claims, often adding specific details or narrowing the scope of the invention[3].

Subject Matter Eligibility

The subject matter eligibility of claims, particularly in the context of software and AI-related inventions, has become increasingly complex. The recent USPTO guidance update on AI patents emphasizes the importance of integrating judicial exceptions into practical applications to ensure patent eligibility. For example, a claim that merely involves abstract ideas or mathematical calculations would not be patent-eligible unless it is integrated into a practical application that imposes meaningful limits on the exception[1].

Patent Landscape in 1993

Technological Advancements

In 1993, the technological landscape was vastly different from today. The internet was in its early stages, and software patents were becoming more prevalent. This period saw significant innovations in computer hardware and software, setting the stage for the digital revolution of the following decades.

Legal Framework

The legal framework governing patents in 1993 was based on the Patent Act of 1952 and subsequent amendments. The courts were beginning to grapple with the patentability of software and other intangible inventions. The concept of "business method patents" was also emerging, which would later become a contentious issue in patent law[2].

Determining Inventorship

Inventorship is a critical aspect of patent law, and it has seen significant scrutiny over the years. For Patent 5,234,404, the inventors listed would have had to contribute significantly to the conception and reduction to practice of the invention. Joint inventorship, where multiple individuals collaborate on an invention, is common, and each contributor must have made a significant and inventive contribution to the subject matter of the patent claims[2].

Search and Analysis Tools

Public Search Facilities

The USPTO provides various tools for searching and analyzing patents, including the Public Search Facility and Patent and Trademark Resource Centers (PTRCs). These resources allow practitioners to search existing patents, published patent applications, and other documentation to ensure the novelty and non-obviousness of their inventions[4].

Global Dossier and Common Citation Document

Tools like the Global Dossier and Common Citation Document (CCD) facilitate the search process by providing access to file histories of related applications and consolidated citation data from multiple IP offices. These tools are essential for conducting thorough prior art searches and understanding the global patent landscape[4].

Implications for Modern Patent Practitioners

AI and Software Patents

The recent USPTO guidance update on AI patents highlights the evolving nature of patent law. Modern practitioners must ensure that AI-related claims integrate judicial exceptions into practical applications, providing meaningful limits and concrete technological improvements. This approach ensures that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Small Claims Patent Court

There is ongoing discussion about the feasibility of a small claims patent court, which could significantly impact how patent disputes are handled. Such a court would aim to provide a more streamlined and cost-effective process for resolving patent infringement cases, particularly for small entities and individual inventors[5].

Key Takeaways

  • Claims Analysis: Understanding the structure and scope of patent claims is crucial for determining the patentability and enforceability of an invention.
  • Subject Matter Eligibility: Ensuring that claims integrate judicial exceptions into practical applications is essential for overcoming section 101 rejections.
  • Inventorship: Correctly determining inventorship is vital to maintain the enforceability of a patent.
  • Search and Analysis Tools: Utilizing public search facilities, Global Dossier, and CCD can enhance the efficiency and accuracy of prior art searches.
  • Evolving Patent Landscape: Staying updated with recent guidance updates and legal developments, such as those related to AI and small claims courts, is essential for effective patent practice.

FAQs

What is the significance of integrating judicial exceptions into practical applications in patent claims?

Integrating judicial exceptions into practical applications ensures that the claim imposes meaningful limits on the exception, transforming it into patent-eligible subject matter. This is crucial for overcoming section 101 rejections, especially in software and AI-related inventions[1].

How does the USPTO determine inventorship for patent applications?

Inventorship is determined based on who conceived the idea and reduced it to practice. Joint inventorship occurs when multiple individuals collaborate, each contributing significantly to the subject matter of the patent claims[2].

What tools are available for searching and analyzing patents?

The USPTO provides tools such as the Public Search Facility, Patent and Trademark Resource Centers (PTRCs), Global Dossier, and Common Citation Document (CCD) to facilitate thorough searches and analysis of patents[4].

What is the current status of the small claims patent court proposal?

The Administrative Conference of the United States (ACUS) has conducted a study on the feasibility of a small claims patent court, gathering input from various stakeholders. The proposal aims to create a more streamlined process for resolving patent disputes, particularly for small entities and individual inventors[5].

How has the patent landscape changed since the issuance of Patent 5,234,404 in 1993?

The patent landscape has evolved significantly, with advancements in technology, changes in legal frameworks, and new guidance updates. The rise of AI and software patents has introduced new complexities, and tools like the Global Dossier and CCD have improved the search and analysis process[1][4].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Determining Inventorship for US Patent Applications - Oregon State University
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,234,404

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.